| Literature DB >> 35170199 |
Li-Hua Lyu1, Chun-Yan Zhang1,2, Wen-Jing Yang1, An-Li Jin1, Jie Zhu1, Hao Wang1, Te Liu3, Bei-Li Wang1,4, Jian-Wen Cheng5,6, Xin-Rong Yang5,6, Wei Guo1,2,4,7.
Abstract
Accumulating evidence suggests that circular RNAs (circRNAs) play essential roles in regulating cancer progression, but many circRNAs in hepatocellular carcinoma (HCC) remain unknown. Dysregulated circRNAs in HCC were identified through bioinformatics analysis of Gene Expression Omnibus data sets. Quantitative real-time PCR (qRT-PCR), Sanger sequencing, RNase R digestion and actinomycin D treatment were conducted to confirm the characterization of circRNAs. CCK-8, wound-healing and Transwell assays were performed to assess the functional roles of Hsa_circ_0003945 (Circ_0003945) in HCC cell lines. Subcellular fractionation and fluorescence in situ hybridization (FISH) were performed to locate Circ_0003945 in HCC cells. Dual-luciferase reporter assay was executed to verify the binding of Circ_0003945 to microRNAs (miRNAs) or the miRNAs to their target genes. In this study, we found that Circ_0003945 was upregulated in HCC tissue, and higher Circ_0003945 expression was positively correlated with tumour size and tumour stage. Furthermore, high plasma levels of circulating Circ_0003945 were confirmed in HCC patients compared with those in non-HCC groups. The functional experiments revealed that overexpression or knockdown of Circ_0003945 promoted or attenuated tumour growth and migration, respectively. Mechanistically, Circ_0003945 might exert as a miR-34c-5p sponge to upregulate the expression of leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4), activating the β-catenin pathway, and finally facilitating HCC progression. Additionally, a β-catenin activator could reverse the effect of Circ_0003945 knockdown. In conclusion, Circ_0003945 exerts a tumour-promoting role in HCC cells by regulating the miR-34c-5p/LGR4/β-catenin axis, which may be a potential target for HCC therapy.Entities:
Keywords: Circ_0003945; hepatocellular carcinoma; leucine-rich repeat-containing G protein-coupled receptor 4; miR-34c-5p; tumour progression
Mesh:
Substances:
Year: 2022 PMID: 35170199 PMCID: PMC8995453 DOI: 10.1111/jcmm.17243
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
FIGURE 1Characteristics and expression of Circ_0003945 in HCC samples. (A) Sanger sequencing of the qPCR product. Red arrow indicates the back‐splicing sites of Circ_0003945. (B) The qPCR analysis of Circ_0003945 and associated UBAP2 in HCC cells treated with or without RNase R. (C) Expression levels of Circ_0003945 and UBAP2 mRNA was determined in HCC cells treated with actinomycin D at indicated time points. (D) Expression level of Circ_0003945 was analysed by qPCR in adjacent neighbouring liver (ANL) and HCC tissue; paired t‐test was used. (E) Relative expression level of circulating Circ_0003945 in plasma; non‐parametric test was used. The RNase R treatment and actinomycin D experiments were performed in triplicate and t‐tests were used. (**p < 0.01; ***p < 0.001)
Correlations between Circ_0003945 expression level and clinicopathological characteristics in HCC
| Clinicopathological characteristics | Circ_0003945 | ||
|---|---|---|---|
| Low | High |
| |
| 25 | 25 | ||
| Age | 0.156 | ||
| <60 | 9 | 14 | |
| ≥60 | 16 | 11 | |
| Gender | 0.462 | ||
| Male | 19 | 22 | |
| Female | 6 | 3 | |
| Liver cirrhosis | 0.777 | ||
| Yes | 12 | 13 | |
| No | 13 | 12 | |
| Tumour number | 0.247 | ||
| Solidarity | 19 | 23 | |
| Multiple | 6 | 2 | |
| Tumour Size (cm) | 0.009 | ||
| ≤5 | 14 | 5 | |
| >5 | 11 | 20 | |
| Tumour encapsulation | |||
| Complete | 10 | 9 | 0.771 |
| None | 15 | 16 | |
| Tumour differentiation | 0.156 | ||
| I‐II | 14 | 9 | |
| III‐IV | 11 | 16 | |
| Microvascular invasion | 0.544 | ||
| No | 7 | 9 | |
| Yes | 18 | 16 | |
| CNLC | 0.023 | ||
| I | 15 | 7 | |
| II+III | 10 | 18 | |
| AFP (ng/ml) | 0.556 | ||
| <20 | 10 | 8 | |
| ≥20 | 15 | 17 | |
CNLC, China liver cancer staging; AFP, alpha fetoprotein.
FIGURE 2Effects of Circ_0003945 on proliferation, migration and invasion of HCC cells. (A) Relative expression level of Circ_0003945 in LO2 normal hepatocytes and HCC cell lines. (B and C) Expression of Circ_0003945 in stably transfected HCC cells. (D and E) Effect of Circ_0003945 knockdown or overexpression on the proliferation of HCC cells was monitored via CCK‐8 assays. (F and G) Migratory ability was assessed by wound‐healing assays in Circ_0003945‐knockdown or overexpressing HCC cells. Scale bar = 100 μm. (H and I) Migratory ability was measured by Transwell assay in Circ_0003945‐knockdown or overexpressing HCC cells. Scale bar = 50 μm. All in vitro experiments were performed in triplicate and t‐tests were used. (*p < 0.05; **p < 0.01; ***p < 0.001, ns, not significant)
FIGURE 3Circ_0003945 acts as miR‐34c‐5p sponge in HCC cells. (A) The location of Circ_0003945 was confirmed by subcellular fractionation. (B) FISH analysis was performed to observe the cellular location of Circ_0003945, 18S rRNA and U6 in MHCC97H cells. Circ_0003945, 18S rRNA and U6 probe were labelled with Cy3 (red) and nuclei were counterstained with DAPI (blue). Scale bar = 20 μm. (C) RIP experiment was performed to co‐immunoprecipitate AGO2 complex. (D and E) Relative luciferase activity in HEK‐293T cells co‐transfected with miR‐34c‐5p or miR‐571 and Circ_0003945‐WT or Circ_0003945‐Mut vector. (F) Expression level of miR‐34c‐5p was determined by qPCR and paired t‐test was used. (G) Correlation between miR‐34c‐5p and Circ_0003945 in tissue samples was evaluated using Spearman correlation analysis. (H) Expression level of miR‐34c‐5p in Circ_0003945‐knockdown HCC cells. All in vitro experiments were performed in triplicate and t‐test were used. (*p < 0.05; **p < 0.01; ns, not significant)
FIGURE 4Enhanced expression of Circ_0003945 attenuates miR‐34c‐5p‐mediated role of HCC progression in vitro. (A and B) Viability of HCC cells with changing expression of Circ_0003945 or miR‐34c‐5p or both via CCK‐8 assay. (C and D) Migratory ability of HCC cells with altering expression of Circ_0003945 and miR‐34c‐5p assessed by wound‐healing assay. Scale bar = 100 μm. (E and F) The migratory ability of HCC cells with changing expression of Circ_0003945 and miR‐34c‐5p was assessed by Transwell assay. Scale bar = 50 μm. All in vitro experiments were performed in triplicate and t‐tests were used. (*p < 0.05; **p < 0.01)
FIGURE 5Circ_0003945 contributes to HCC progression by regulating LGR4. (A) Western blot analysis of LGR4 in Circ_0003945‐knockdown HCC cells. (B) Level of LGR4 in HCC cells with Circ_0003945‐knockdown or miR‐34c‐5p alteration. (C) The correlation between LGR4 and Circ_0003945 expression; Spearman's rank correlation test was used. (D and E) Proliferation assay of HCC cells with silencing or overexpressing Circ_0003945 and LGR4. (F‐I) Migration of HCC cells after silencing or overexpressing Circ_0003945 and LGR4. For F and G, scale bar = 100 μm, for H and I, scale bar = 50 μm. Functional experiments were performed in triplicate and t‐tests were used. (*p < 0.05; **p < 0.01; ***p < 0.001)
FIGURE 6β‐Catenin pathway was finally activated by Circ_0003945/miR‐34c‐5p/LGR4 to promote HCC progression. (A) Western blot analysis of the β‐catenin pathway induced by the Circ_0003945/miR‐34c‐5p axis in HCC cells. (B) The effect of β‐catenin activator on Circ_0003945‐knockdown HCC cells. (C) Measurement of proliferation of HCC cells treated with β‐catenin activator after silencing of Circ_0003945 in HCC cells. (D‐E) Migratory ability of decreasing‐Circ_0003945‐HCC cells after treatment with β‐catenin activator. For figure D, scale bar = 100 μm. For figure E, scar bar = 50 μm. All experiments were performed in triplicate and t‐tests were used. (*p < 0.05; **p < 0.01; ***p < 0.001)
FIGURE 7Circ_0003945 promotes the growth and metastasis of HCC cells in vivo. (A) Tumours were dissected from nude mice subcutaneously injected with Circ_0003945‐knockdown or control MHCC97H cells. (B and C) Weight and volume of subcutaneous xenograft tumours isolated from nude mice. (D) Representative images of immunohistochemical analysis to detect Ki‐67. Scar bar = 50 μm. (E) Schematic diagram indicating the underlying mechanism by which Circ_0003945 enhances HCC progression via the miR‐34c‐5p/LGR4 axis. (*p < 0.05; **p < 0.01; ***p < 0.001)